Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

OBJECTIVE: Dapagliflozin, a highly selective inhibitor of the renal sodium-glucose cotransporter-2, increases urinary excretion of glucose and lowers plasma glucose levels in an insulin-independent manner. We evaluated the efficacy and safety of dapagliflozin in treatment-naive patients with type 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrannini, Ele, Ramos, Silvia Jimenez, Salsali, Afshin, Tang, Weihua, List, James F.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945163/
https://www.ncbi.nlm.nih.gov/pubmed/20566676
http://dx.doi.org/10.2337/dc10-0612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945163/
https://www.ncbi.nlm.nih.gov/pubmed/20566676
http://dx.doi.org/10.2337/dc10-0612

Ejemplares similares